Read by QxMD icon Read

cannabinoid hyperemesis

David I Zimmer, Ross McCauley, Varun Konanki, Joseph Dynako, Nuha Zackariya, Faadil Shariff, Joseph Miller, Sophia Binz, Mark Walsh
Background. Chronic cannabis use has become prevalent with decriminalization, medical prescription, and recreational legalization in numerous US states. With this increasing incidence of chronic cannabis use a new clinical syndrome has become apparent in emergency departments and hospitals across the country, termed Cannabinoid Hyperemesis (CH). CH has been described as cyclical vomiting and abdominal pain in the setting of chronic cannabis use, which is often temporarily relieved by hot showers. CH presents a diagnostic challenge to clinicians who do not have a high clinical suspicion for the syndrome and can result in high costs and resource utilization for hospitals and patients...
2019: Journal of Addiction
Kamal Kant Sahu, Ajay Mishra, Leily Naraghi
No abstract text is available yet for this article.
January 29, 2019: BMJ Case Reports
Eike Blohm, Peter Sell, Mark Neavyn
PURPOSE OF REVIEW: The advent of legalized cannabis in multiple regions of the United States has rendered the drug more accessible to pediatric patients. Pediatricians and Pediatric Emergency Medicine Providers face new challenges in counseling both patients and their parents, diagnosing exploratory ingestions of cannabinoids in toddlers, and managing complications of prolonged, heavy cannabis use in adolescents. The purpose of this review article is to provide clinicians a succinct summary of recent literature regarding tetrahydrocannabinol (THC) pharmacokinetics, pharmacodynamics, impacts on development, as well as presentations of acute and chronic toxicity...
January 28, 2019: Current Opinion in Pediatrics
Charisse Pizarro-Osilla
No abstract text is available yet for this article.
November 2018: Journal of Emergency Nursing: JEN: Official Publication of the Emergency Department Nurses Association
Lawrence A Szarka, Michael Camilleri
There is substantial overlap between the symptoms of gastroparesis and a variety of alternative disorders. These conditions include rumination syndrome, drug-induced gastric emptying delay, cannabinoid hyperemesis syndrome, and eating disorders, which can be identified based on the history alone. The remaining patients require a diagnostic approach of physical examination, laboratory tests, evaluation with esophagogastroduodenoscopy or contrast radiography, and a test to measure gastric emptying. Symptomatic patients who have normal nutritional status and gastric emptying that is either normal or mildly delayed should be diagnosed with functional dyspepsia, whereas patients with moderate or severe gastric emptying delay are diagnosed with gastroparesis...
January 2019: Gastrointestinal Endoscopy Clinics of North America
Joana Dida, Noorin Walji
A short-cut review was carried out to establish whether haloperidol is effective at treating the symptoms of cannabinoid hyperemesis syndrome (CHS). One study was directly relevant to the question. The author, date and country of publication, patient group studied, study type, relevant outcomes, results and study weaknesses of that paper were tabulated. The clinical bottom line was that no controlled studies exist to report on the use of haloperidol. Alternative agents, used mainly off-label, show better promise at effectively treating symptoms of CHS based on case series and reports...
November 2018: Emergency Medicine Journal: EMJ
Hyunyoung G Kim, Jeremiah Moon, Heather Dixon, Paul Tullar
Background: Cannabinoid hyperemesis syndrome is a condition characterized by chronic cannabis use and cyclic episodes of nausea, vomiting, and abdominal pain, relieved by compulsive bathing. The syndrome is likely to be underdiagnosed in pregnant women due to its similarity with hyperemesis gravidarum in the presentation. Case: We report a 20-year-old pregnant woman with multiple admissions for recurrent nausea and vomiting who was observed to be taking frequent hot showers...
2018: Case Reports in Obstetrics and Gynecology
Judith Klassen, Gail Wilson
Rationale: With marijuana legalization, clinicians need to be aware of Cannabinoid Hyperemesis Syndrome (CHS), which may masquerade as other disease states such as uremia. Presenting concerns of the patient: A 37-year-old man with bipolar affective disease treated with lithium had progressive renal insufficiency presumably on the basis of interstitial fibrosis. He developed persistent and severe nausea and vomiting which was assumed to be on the basis of uremia...
2018: Canadian Journal of Kidney Health and Disease
Maximilian Gericke, Dirk Hartmann
HISTORY:  The 43-year-old patient was admitted because of vomiting and abdominal pain. He had a history of depression and multiple discus prolapses. He reported the consumption of three beers per day. FINDINGS:  The patient presented diffuse abdominal pain. The serume-kreatine was elevated (205 µmol/l), there was a leucocytosis (18,4^3/µl) and a mild elvation of y-GT (2,3µkat/l). Stool culture was negative. An abdominal ultrasound and a gastroscopy did not show groundbreaking findings...
August 2018: Deutsche Medizinische Wochenschrift
Molly V Williams
Despite current legal and medical controversies surrounding cannabinoids, it is a fact that emergency departments are seeing an increasing number of patients presenting with symptoms associated with the use of these drugs. This review outlines the pathophysiology of cannabinoids, the potential clinical findings associated with their use, and the current evidence for best-practice management of patients who present to the emergency department with signs of acute intoxication and chronic use. Differences between natural and synthetic cannabinoids are discussed, along with the latest evidence for diagnosing and managing patients presenting with the intractable vomiting of cannabinoid hyperemesis syndrome...
August 2018: Emergency Medicine Practice
Jessica Rice, Michelle Cameron
PURPOSE OF REVIEW: Cannabis and cannabinoids have been used medically and recreationally for thousands of years and recently there has been a growing body of research in this area. With increased access now that medical marijuana is available in many jurisdictions, patients and providers want to know more about the evidence for benefits and risks of cannabinoid use. This paper provides an overview of the available cannabinoid-based formulations, a summary of the highest quality evidence for the use of cannabinoids for treating spasticity and pain associated with multiple sclerosis (MS), and a discussion of possible dosing regimens based on information from these studies...
June 19, 2018: Current Neurology and Neuroscience Reports
Elena Fradkov, Grigoriy E Gurvits
No abstract text is available yet for this article.
June 15, 2018: Inflammatory Bowel Diseases
Mahra Nourbakhsh, Angela Miller, Jeff Gofton, Graham Jones, Bamidele Adeagbo
Cannabinoid hyperemesis syndrome (CHS) is one of the more clinically challenging effects of cannabis consumption. It is characterized by cyclic attacks of nausea and vomiting in chronic cannabinoid users and learned behavior of compulsive hot bathing. The deaths of a 27-year-old female, a 27-year-old male, and a 31-year-old male with a history of CHS are reported. The decedents had a history of cyclical nausea and vomiting, chronic cannabinoid use and negative laboratory, radiological and endoscopic findings...
May 16, 2018: Journal of Forensic Sciences
Eduardo Valdivielso Cortázar, Patricia Ucha Abal, Pedro Alonso Aguirre
We report the case of a 30-year-old female with a history of cannabis use from 16 years of age. The patient presented to the Gastroenterology Clinic due to cyclical epigastric pain associated with postprandial stomach heaviness, nausea and vomiting. She was admitted due to a worsening of her condition, which prevented her from leading a normal life.
May 2018: Revista Española de Enfermedades Digestivas
M Camilleri
BACKGROUND: Cannabinoid agents and cannabis are frequently used for relief of diverse gastrointestinal symptoms. PURPOSE: The objective of this article is to increase the awareness of gastroenterologists to the effects of cannabinoids on gastrointestinal motility, as gastroenterologists are likely to encounter patients who are taking cannabinoids, or those with dysmotility that may be associated with cannabinoid mechanisms. The non-selective cannabinoid agonist, dronabinol, retards gastric emptying and inhibits colonic tone and phasic pressure activity...
September 2018: Neurogastroenterology and Motility: the Official Journal of the European Gastrointestinal Motility Society
Jeff Lapoint, Seth Meyer, Charles K Yu, Kristi L Koenig, Roneet Lev, Sayone Thihalolipavan, Katherine Staats, Christopher A Kahn
Introduction: Cannabinoid hyperemesis syndrome (CHS) is an entity associated with cannabinoid overuse. CHS typically presents with cyclical vomiting, diffuse abdominal pain, and relief with hot showers. Patients often present to the emergency department (ED) repeatedly and undergo extensive evaluations including laboratory examination, advanced imaging, and in some cases unnecessary procedures. They are exposed to an array of pharmacologic interventions including opioids that not only lack evidence, but may also be harmful...
March 2018: Western Journal of Emergency Medicine
Diane Portman, Kristine A Donovan
No abstract text is available yet for this article.
May 2018: Journal of Oncology Practice
Francesc Torres, Vanessa Laveglia, Cristina Molera, Mariona Bonet
No abstract text is available yet for this article.
November 2018: Anales de Pediatría: Publicación Oficial de la Asociación Española de Pediatría (A.E.P.)
Andrew M Moon, Sarah A Buckley, Nicholas M Mark
Cannabinoid hyperemesis syndrome (CHS) is a clinical entity in which marijuana users develop nausea, vomiting, and abdominal pain that improves with hot water bathing or cannabis cessation. Previous models suggest that CHS arises solely from the derangement of cannabinoid receptor type 1 signaling. However, involvement of transient receptor potential vanilloid subtype 1 (TRPV1) receptor, which is activated by marijuana, capsaicin, and heat, could fill gaps in existing models, including the enigmatic role of hot water bathing...
2018: ACG Case Reports Journal
Joseph Habboushe, Ada Rubin, Haoming Liu, Robert S Hoffman
Epidemiological data, including prevalence, for cannabinoid hyperemesis syndrome (CHS) remain largely unknown. Without these data, clinicians often describe CHS as 'rare' or 'very rare' without supporting evidence. We seek to estimate the prevalence of CHS in a population of patients presenting to a socio-economically and racially diverse urban Emergency Department of a public hospital. This study consisted of a questionnaire administered to a convenience sample of patients presenting to the ED of the oldest public hospital in the United States...
June 2018: Basic & Clinical Pharmacology & Toxicology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"